ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 225.3 CHF | -1.50% |
|
-58.28% | -58.28% |
| Sales 2024 * | 42.98B 38.62B 58.86B | Sales 2025 * | 52.62B 47.28B 72.06B | Capitalization | 811B 729B 1,111B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 10.72B 16.34B | Net income 2025 * | 16.55B 14.87B 22.67B | EV / Sales 2024 * | 19.3 x |
| Net Debt 2024 * | 18.06B 16.22B 24.73B | Net Debt 2025 * | 15B 13.47B 20.54B | EV / Sales 2025 * | 15.7 x |
| P/E ratio 2024 * |
67.4
x | P/E ratio 2025 * |
48.5
x | Employees | 43,000 |
| Yield 2024 * |
0.58% | Yield 2025 * |
0.66% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -1.50% | ||
| 1 week | -58.28% | ||
| Current month | -58.28% | ||
| 1 month | -58.28% | ||
| 3 months | -58.28% | ||
| 6 months | -58.28% | ||
| Current year | -58.28% |
1 year
225.31
540.00
3 years
210.33540.00
5 years
108.90540.00
10 years
54.85540.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-26 | - | +-NaN% | 471 |
| 24-06-25 | - | +-NaN% | 933 |
| 24-06-24 | - | +-NaN% | 636 |
| 24-06-21 | - | +-NaN% | 375 |
| 24-06-20 | - | +-NaN% | 941 |
Delayed Quote London S.E., December 10, 2021 at 09:37 am
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.62% | 640B | |
| -6.98% | 353B | |
| +19.08% | 333B | |
| +9.05% | 302B | |
| +16.30% | 246B | |
| +2.41% | 225B | |
| +12.47% | 218B | |
| +8.91% | 168B | |
| -3.44% | 155B |
- Stock Market
- Equities
- LLY Stock
- LEL Stock
